Hypertension
Conditions
Interventions
Experiment group:precision medication strategies based on pharmacogenomics
Control group: traditional medication strategies
Observation group:health follow-up visits
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
55 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Permanent residents of all townships of the Dajie and Jiuzhi towns in Daming County, of any gender, aged 55 and above. 2. Diagnosed with primary hypertension, after continuous medication treatment for at least 2 weeks before enrollment, systolic blood pressure =140mmHg (=150mmHg for those aged above 65 years) or diastolic blood pressure =90mmHg, or both. Clinical diagnosis is according to ICD10 coding rules as I10.x00-x05. 3. Expected survival period =3 months. 4. Be able to provide accurate and reliable information related to drug treatment and efficacy evaluation. 5. Consent to adhere to medication plan adjustments and follow-ups as prescribed by the research physician.
Exclusion criteria
Exclusion criteria: 1. Unwillingness or inability to provide truthful and reliable information for any reason. 2. Presence of co-existing infectious diseases (such as active Hepatitis B or C infection, tuberculosis, etc.) or severe life-threatening conditions, including malignant tumors. 3. Liver function impairment (AST and/or ALT levels =2.5 times the upper limit of normal, total bilirubin =1.5 times the upper limit of normal) or kidney function impairment (creatinine clearance rate <30mL/min as calculated by the Cockcroft-Gault formula), which could affect the selection of therapeutic drugs. 4. Incomplete data related to research evaluation indicators. Incomplete data related to research evaluation indicators, including but not limited to: a. Absence of core efficacy evaluation indicators such as systolic and diastolic blood pressure, heart rate, fasting blood glucose, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides. b. Inability to collect data on adverse reactions necessary for clinical research, including relevant drugs, manifestations of adverse reactions, timing, discontinuation of suspected drugs, and reactions to re-administration. c. Inability to provide medication adherence scores and quality of life information for any reason. 5. Known or suspected inability to comply with the research protocol, such as due to alcohol abuse, drug dependence, or mental disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Control rate for blood pressure; | — |
Secondary
| Measure | Time frame |
|---|---|
| Control rate for blood pressure stratified by cardiovascular risk level;Time for control of blood pressure;Adverse event rate;Health self assessment;Medication compliance;medicine cost of hypertension treatment;total cost of hypertension treatment; | — |
Countries
China
Contacts
Public ContactLiu Lihong
China-Japan Friendship Hospital
Outcome results
None listed